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Abstract Cbimeric receptor subunits of the AMPA receptor 
subunit GluR2 and the kainate receptor subunit GluR6 were 
constructed and stably expressed in baby hamster kidney cells. 
By using Ca*+ imaging and radioligand binding, we demonstrated 
that substitution of a specific domain showing homology to a 
bacteria1 leucine-isoleucine-valine binding protein (LIVBP) bad 
no effect on the affinities of the tested agonists, but decreased the 
affinities of the antagonists CNQX, DNQX, and NBQX. On the 
other band, when the first of two domains showing homology to 
a bacteria1 glutamine binding protein (QBP) in GluR2 was substi- 
tuted with the corresponding region from GluR6, the affinity of 
AMPA decreased sevenfold and the affinity of kainate increased 
fourfold, indicating the importance of this domain in binding of 
these agonists. In contrast to this, the affinities of quisqualate and 
domoate, two other agonists, were unchanged, indicating that a 
region located C-terminal to the QBP domain is also involved in 
agonist binding. 
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1. Introduction 
L-Glutamate (L-Glu) is the most prevalent excitatory neuro- 
transmitter in the central nervous system and is believed to play 
a key role in the mediation of fast synaptic transmission. Fur- 
thermore, L-Glu is probably involved in memory and learning, 
as well as in several neurological diseases [ 1,2]. 
Receptors for L-Glu are classified into ionotropic and 
metabotropic receptors. Based on pharmacology and electro- 
physiology, the ionotropic receptors have been further subdi- 
vided into N-methyl-D-aspartate (NMDA), a-amino-3-hy- 
droxy-5-methyl-4-isoxazole propionate (AMPA), and kainate 
receptors [3]. At present, four AMPA receptor subunits, 
GluR14 [&6], and five kainate receptor subunits, GluRS-7 
[7-91 and KA-l/KA-2 [lO,ll], have been cloned. In heterolo- 
gous systems, GluRI4 form functional homomeric channels 
with high affinity for AMPA and quisqualate, and low affinity 
for kainate and domoate. In contrast, homomeric receptors of 
GluR5-7 and KA-l/KA-2 show high affinity for kainate and 
domoate, and very low affinity for AMPA. Several edited var- 
iants of the receptor subunits have been identified. Most impor- 
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tant is the Q586R editing of GluR2 [ 121, rendering the receptor 
impermeable to Ca*’ [13]. 
The first predicted topology model for the AMPA/KA recep- 
tor subunits suggested the presence of a long extracellular N- 
terminus followed by four transmembrane domains (TMD1-4), 
and a short extracellular C-terminus [4]. However, recently this 
model has been brought into question [l&16] as experiments 
have indicated that the C-terminus is intracellular [ 17,181, and 
that at least part of the loop between TMD3 and TMD4 is 
extracellular. This is in disagreement with the four TMD model 
which places the loop between TMD3 and TMD4 intracellu- 
larly. At present, both a five and a three TMD model have been 
proposed [16,18,19]. 
Two bacterial binding proteins, a glutamine binding protein 
(QBP) [20] and a leucine-isoleucine-valine binding protein 
(LIVBP) [21], have been aligned to the ionotropic GluRs 
[22,23]. LIVBP shows homology with the AMPA/KA receptor 
subunits in a domain between residues 1 and 400, whereas QBP 
aligns to two domains, one located between residues 400 and 
500, and another located between the original TMD3 and 
TMD4 (residues -720-760). Previous studies, where point muta- 
tions were introduced in the first QBP domain, have suggested 
that this domain is involved in agonist binding [24,25]. This 
hypothesis is supported by the observation that the two QBP 
domains, but not the LIVBP domain, are also found in two 
kainate binding proteins from frog and chick brain [26,27]. 
In order to localize domains important for ligand binding, 
we have generated four chimeric receptor subunits from GluR2 
and GluR6, exchanging either the LIVBP or the first QBP. The 
homomeric receptors were stably expressed in baby hamster 
kidney (BHK) cells, and functionality and ligand binding prop- 
erties were investigated. Parts of this study (pharmacology and 
function of GluR6 and GluR2(Q)) have previously been pre- 
sented in [28-301. 
2. Materials and methods 
2.1. Construction of mutant receptor subunits 
2.1.1. Chimeras. The first GlnH domain was defined as amino acid 
K393%Q508 in GluR2, and amino acid R40&N515 in GluR6 [22]. The 
LIV domain was defined as amino acid Vl-1365 in GluR2 and amino 
acid Tl-1371 in GluR6 (both amino acids are included and the signal 
peptides are excluded). The chimeric cDNAs were generated by conven- 
tional polymerase chain reaction (PCR) methods using Pfu polymerase 
(Stratagene, La Jolla, CA) or AmpliTaq DNA polymeraie CPerkin- 
Elmer/Cetus. Norwalk, CT) for 25 cvcles of 1 min at 94°C. 2 min at 
4O”C, and 2 min at 72°C. The final PCR constructs were sequenced by 
the method of Sanger et al. [31]. All chimeric constructs were incorpo- 
rated into Zem219b [32], which utilizes the constitutively active mouse 
metallothionein promoter for expression, and the dihydrofolate reduc- 
tase gene for selection of stable transformants. 
2.1.2. GluRZ(Q). A -700 bp fragment was generated from three 
PCR reactions using GluR2(R) cDNA as template. One of the primers 
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hybridized to a region containing bp G1757 (excluding the signal pep- 
tide sequence), however, the primer contained a mismatch in the posi- 
tion corresponding to bp 1757 (creating a G + A substitution), resulting 
in the R586Q mutation. The fragment was digested with SpeIIBspEI 
(New England BioLabs) and assembled with the rest of GluR2. The 
GluR2(Q) cDNA was inserted into Zem219b, and the PCR fragment 
was sequenced. 
2.2. Expression sysrem and generation of cell lines 
For transfection, the DNA was purified using CsCl centrifugation. 
The plasmids were transfected into BHK570 cells by Lipofectin (BRL), 
and colonies were isolated as described previously [30]. The selected 
clones were screened for receptor expression by Western blotting. The 
cell lines were grown in standard high-glucose Dulbecco’s modified 
Eagle’s medium with Glutamax (Gibco-BRL), with the addition of 10% 
fetal calf serum and 5 PM methotrexate. 
2.3. [‘H]Kainate binding 
Confluent cells were washed twice with phosphate-buffered saline at 
25°C followed by incubation for 30 min with 10 ml of 10 mM EDTA. 
The cells were scraped off, and membrane preparation and radioligand 
binding was carried out as described in Tygesen et al. [30]. The final 
urotein concentration in the assav was 0.05-0.2 mg/ml (GluR6. GluR6I 
LIVBP, GluR2). Non-specific binding was defined‘ as [‘Hlkainate 
bound in the presence of 1 mM L-Glu. [3H]Kainate (58 Ci/mmol) was 
purchased from NEN-DuPont. 
2.4. [‘H/AMPA binding 
Confluent cells were scraped off, and membrane preparation and 
radioligand binding was performed as described in Tygesen et al. [30]. 
The final protein concentration in the assay was 0.05-0.1 mg/ml 
(GluR2/LIVBPGluR6), 0.3 mg/ml (GluR2(Q)), or 0.6 mg/ml (GluR2/ 
QBPGluR6), depending on the level of receptor expression. Non-spe- 
cific binding was defined as [‘HIAMPA bound in the presence of 1 mM 
L-Glu. [3H]AMPA (46.1 Ci/mmol) was purchased from NEN-DuPont. 
All binding data were analyzed with EBDA-SCARFIT (Elsevier- 
Biosoft, Cambridge, UK). Data are expressed as mean + SD. 
2.5. Western blot analysis 
Samples were subjected to SDS-PAGE (420% gradient gels) and 
transferred to a nitrocellulose membrane by electroblotting (200 mA, 
2 h). The blots were blocked for 30 min with 3% non-fat dry milk in 
Tris-buffered saline (TBS) at room temperature followed by incubation 
for 2 h at room temperature with affinity-purified GluR6- or GluR2- 
specific anti-peptide antibody (GluR6, amino acids 862-877; GluR2, 
amino acids 843-862; kindly supplied by Dr. Craig Blackstone) [33,34] 
diluted 1 :200 in 1.5% non-fat dry milk in TBS. Following several 
washes in TBS, 0.1% Tween 20, the blot was incubated for 1 h with 
horseradish peroxidase-conjugated anti-rabbit IgG (Dako P217) di- 
luted 1 :2000 in 1.5% non-fat dry milk in TBS. After washes, im- 
munoreactive protein was visualized with ECL detection reagent 
(Amersham). 
2.6. Protein determination 
Protein contents were determined by the Bradford (Bio-Rad) assay 
using gamma-globulin as a standard. 
2.7. Imaging analysis 
The imaging analysis was performed essentially as decribed in 
Tygesen et al. [30]. In some experiments (GluR6, GluR6/LIVGluR2, 
GluR6/QBPGluR2), the extracellular solution contained N-methyl-o- 
glucamine (NMG) instead of NaCl. Eventually the cells were incubated 
with 1 mg/ml concanavalin A (Con A) prior to analysis in order to 
inhibit receptor desensitization [8,35]. 
3. Results 
3.1. Western blotting 
Membrane preparations of rat brain, wild-type BHK cells, 
and BHK cells transfected with the native and mutant receptor 
cDNAs were subjected to SDS-PAGE and to immunoblot anal- 
ysis using GluR6- or GluR2-specific antibodies. A protein of 
approximately 100 kDa was detected in rat brain, and in all 
transfected cell lines, whereas no band was detected in the 
wild-type cell line (Fig. 1). The size of the bands is in accordance 
with the expected molecular weight, and also with data re- 
ported by others [19,33,34]. In one of the cell lines (GluR2(Q); 
Fig. 1B) a doublet band was detected, and in the GluR6 cell 
line, faint bands of higher molecular weight were detected. In 
the cell line expressing the chimera GluR61QBPGluR2, a lower 
molecular weight band was also detected. 
3.2. Radioligand binding studies 
We investigated the binding of [3H]kainate and [3H]AMPA 
to membranes of cells expressing the native and mutant recep- 
tors. For receptor characterization, inhibition studies were per- 
formed in which binding of [3H]kainate and [3H]AMPA com- 
peted against the non-NMDA agonists AMPA, kainate, quis- 
qualate, domoate, and L-Glu, and the non-NMDA antagonists 
CNQX, DNQX, and NBQX. The results from the radioligand 
binding experiments are summarized in Table 1. 
As reported previously [30], binding of [?H]kainate to GluR6 
was saturable and best fitted to a single-site model with a Kd 
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Fig. 1. Western blots of membrane preparations from baby hamster 
kidney cells transfected with native and mutant glutamate receptors, 
using GluR6 (A) or GluR2 (B) specific antibodies recognizing the 
C-terminus. The amount of protein loaded is noted in brackets. (A) lane 
1, GluR6/QBPGluR2 (45 fig); lane 2, GluR6 (5 ,ug); lane 3, GluR6/ 
LIVBPGluR2 (5 pg); lane 4, rat brain (20 fig); lane 5, wild-type cell line 
(20 fig). (B) Lane 1, GluR2/QBPGluR6 (90 fig); lane 2, GluR2/ 
LIVBPGluR6 (5 pg); lane 3, GluR2(Q) (5 pug); lane 4, rat brain (2Opg); 
lane 5, wild-type cell line (20 pg). 
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of 12.9 f 2.4 nM (n = 4). B,,, was followed for several months 
and was determined to be approximately 3 pmol/mg protein. 
[3H]Kainate was most potently displaced by domoate 
(Ki = 5.1 f 3.0 nM, n = 4), whereas AMPA was unable to in- 
hibit the binding (Ki > 15 ,DM) (Table 1). No specific 
[3H]AMPA binding to the GluR6 receptors could be detected. 
In contrast, GluR2(Q) bound [‘HIAMPA with high affinity. 
Scatchard analysis revealed a single binding site with 
K,, = 15.7 ? 4.5 nM (n = 2) [29]. B,,, varied between 0.3 and 2.5 
pmollmg protein, probably as a result of channel opening in- 
duced by L-Glu present in the medium [30]. Quisqualate was the 
most potent inhibitor of [3H]AMPA binding (K, = 10.3 ? 2.1 
nM, n = 2), and kainate was the least potent (K, = 3054 ? 230 
nM, n = 2) (Table 1). 
The chimera GluR6/LIVBPGluR2 (Fig. 2) bound [3H]ka- 
inate with Kd = 13.3 f 1.8 nM and B,,, = 3.0 f 0.4 pmoVmg 
protein (n = 3). No specific [3H]AMPA binding could be de- 
tected. The pharmacological agonist profile closely resembled 
the one obtained for GluR6, with high affinity for domoate 
(K, = 4.0 + 3.0 nM, n = 3) and very low affinity for AMPA 
(K, ~15 ,uM) (Table 1). 
The chimera GluR2/LIVBPGluR6 (Fig. 2) bound 
[3H]AMPA with high affinity (Kd = 10.0 Y! 3.7 nM, n = 4). B,,, 
was 5.3 + 1.8 pmol/mg protein (n = 4). No specific [3H]kainate 
binding could be detected. The pharmacological agonist profile 
closely resembled the one obtained for GluR2(Q), with high 
affinity for quisqualate (K, = 4.7 ? 3.6 nM, n = 3) and low af- 
finity for kainate (K, = 2111 f 484 nM, n = 3) (Table 1). 
The chimera GluR2/QBPGluR6 (Fig. 2) bound [3H]AMPA 
with K,, = 107 + 11 nM and B,,, = 630 f 254 fmol/mg protein 
(n = 4). Thus, the affinity of AMPA had decreased from 15.2 
nM to 107 nM. Quisqualate was still the most potent displacer 
with a K, = 11.7 f 0.4 nM (n = 2) similar to the one found in 
GluR2(Q). Interestingly, the affinity of kainate had slightly 
increased (K, = 716 f 90 nM, n = 2) compared to GluR2(Q), 
indicating the importance of this domain for binding of kainate 
(Table 1). In accordance with the results obtained from inhibi- 
tion of [3H]AMPA binding, the chimera GluR2/QBPGluR6 
only bound [3H]kainate with low affinity. 
Neither specific [3H]AMPA nor [‘Hlkainate binding could be 
detected in four different subclones of BHK cells transfected 
with the chimera GluR6/QBPGluR2. 
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3.3. Functional studies 
The function of the native and mutant receptors was tested 
by Ca*’ imaging, taking Ca2+ influx as a measurement of func- 
tionality. The only mutant which could not be tested was chi- 
mera GluR2/QPBGluR6, as this mutant was generated from 
the GluR2(R) version, and therefore was not permeable to 
Ca”. All other native and mutant receptors were found to be 
functional. 
As we have reported previously [30] 5 ,uM kainate (in NMG 
containing buffer) induced a sustained increase in the intracel- 
lular Ca2’ concentration in 75% (n = 58) of the GluR6 express- 
ing BHK cells (Con A pretreated). The increase in intracellular 
Ca” concentration varied between 200 nM and 3 ,uM. When 
GluR2(Q) expressing cells were stimulated with 200 ,DM kainate 
(in high Na’ buffer, no Con A pretreatment), a similar increase 
in intracellular Ca” concentration was observed in 74% of the 
cells (n = 65). 90% of the cells (n = 41) expressing the chimera 
GluR6/LIVBPGluR2 responded, when stimulated with 100,~M 
kainate (NMG buffer, Con A pretreatment). 81% of the cells 
(n = 32) expressing the chimera GluR2/LIVBPGluR6 re- 
sponded to 500 ,uM kainate (high Na’ buffer, no Con A pre- 
treatment). The cells expressing the chimera GluR6/ 
QBPGluR2 also responded to 500,~M kainate (47% responded, 
n = 15), however, the increase in intracellular Ca2’ was smaller 
(5&300 nM). 
4. Discussion 
BHK570 cells have previously been demonstrated to provide 
a convinient system for stable expression of AMPA/kainate 
glutamate receptors. In this system, the AMPAlkainate recep- 
tors have been studied by radioligand binding, electrophysiol- 
ogy, and Ca2’ imaging [28-30,36,37]. Interestingly, the pharma- 
cological profiles of these stably expressed receptors resemble 
the ones reported from transient systems [5,9,36,38,39]. Fur- 
ther, the pharmacological profile of GluR2(Q) (Table 1) is 
similar to that previously reported for GluR2(R) [5,36,39], thus, 
the R586Q point mutation does not affect the ligand binding 
affinities of GluR2. 
The pharmacological profile of the chimera GluR2/ 
LIVBPGluR6 resembles GluR2, with unchanged (or slightly 
increased) affinities for all agonists. Similarily, the agonist affin- 
Table I 
Binding affinities (K, or Kd, nM) of various agonists and antagonists for GluR2(Q), GluR6, and chimeras hereof 
Compound “GluR2(Q) bGluR6 “GluR2lQBPGluR6 “GluR2/LIVBPGluR6 bGluR6/LIVBPGluR2 
AMPA 15.1 f 4.5 > 15,000 107 f 11 10.0 f 3.7 > 15,000 
Kainate 3054 f 230 12.9 + 2.4 716 f 90 2111 f 484 13.3 + 1.8 
Quisqualate 10.3 * 2.1 203? 114 11.7 f 0.4 4.7 + 3.6 193 f 16 
L-Glu 477 f 91 355 f 74 1344 f 67 203 f 69 565 ? 141 
Domoate 2598 f 230 5.1 f 3.0 3305 f 840 1691 f 503 4.0 + 3.0 
CNQX 184 f 98 528 f 65 1273 f 507 810 f 172 1442 f 316 
DNQX 454 f 55 351 f 130 _ 310 f 30 922 f 287 
NBQX 394 f 229 866 + 118 _ 153 f 105 7499 + 3848 
Values represent mean f S.D. The K,, and K, values are calculated from 24 saturation or displacement experiments performed in duplicate. The 
concentrations of [3H]AMPA were: 18 nM (GluR2(Q)), 25 nM (GluR2/QBPGluR6), 10 nM (GluR2/LIVBPGluR6). The concentrations of [3H]kainate 
were 10 nM. AMPA, a-amino-3-hydroxy-5-methyl-4-isoxazole propionate; CNQX, 6-cyano-7-nitroquinoxaline-2,3-dione; DNQX, 6,7-dinitroqui- 
noxaline-2,3-dione; NBQX, 6-nitro-7-sulfamoylbenzo[f]quinoxaline-2,3-dione. 
a Measured by [3H]AMPA binding. Affinity of AMPA calculated from Scatchard analysis using [3H]AMPA. 
b Measured by [3H]kainate binding. Affinity of kainate calculated from Scatchard analysis using [‘Hjkainate. 
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Fig. 2. Schematic presentation of the native and chimeric receptors 
inserted in the cell membrane. A three transmembrane topology model 
[14-161 is assumed. The N-terminus is extracellular, the C-terminus 
intracellular. 
ities for chimera GluR6/LIVBPGluR2 resemble the affinities 
for GluR6. As both the rank order of affinities and the Ki values 
for five different agonists thus were unchanged, and as both 
receptors were functional when stimulated with kainate, this 
strongly indicates that the LIVBP domain does not play a role 
in agonist binding. 
However, when the first QBP domain in GluR2 is exchanged 
with GluR6 (GluR2/QBPGluR6) the affinities of some of the 
agonists change. Most interesting is the sevenfold decrease in 
affinity of AMPA and the fourfold increase in affinity of ka- 
inate. This indicates that the first QBP domain is directly in- 
volved in binding of both AMPA and kainate. In contrast to 
this, the unchanged affinities of quisqualate and domoate indi- 
cate that the first QBP domain does not selectively contribute 
to the binding of these agonists (even though involvement of 
some residues can not be excluded, however, these residues 
cannot explain the difference in affinities of quisqualate and 
domoate for GluR2 and GluR6). Consequently, the binding of 
quisqualate and domoate directly involves residues located in 
the region C-terminal to the first QBP domain. The C-terminal 
region is probably also involved in binding of AMPA and 
kainate, as the affinity of AMPA further decreases from 107 
nM in chimera GluR2/QBPGluR6 to ~15 PM in chimera 
GluR6/LIVBPGluR2, and the affinity of kainate increases 
from 716 nM in chimera GluR2/QBPGluR6 to 13 nM in chi- 
mera GluR6/LIVBPGluR2. Chimera GluR2/QBPGluR6 could 
not be tested for functionality, as it was generated from the 
Ca*’ impermeable version of GluR2 (the R version). However, 
the increase in affinity of kainate and the unchanged affinities 
of quisqualate and domoate strongly indicates that the receptor 
has been properly processed. 
When we turn to the antagonists, CNQX, DNQX, and 
NBQX, the affinities for chimera GluR2/LIVBPGluR6 and 
GluR6/LIVBPGluR2, decrease compared to GluR2(Q) and 
GluR6, respectively (Table 1). Along with the unchanged ag- 
onist affinities and the demonstrated functionality, this indi- 
cates that the LIVBP domain is involved in antagonist binding. 
The first QBP domain might also be involved, as the CNQX 
affinity decreases by a factor of seven in GluR2/QBPGluR6 
compared to GluR2. 
Our agonist studies are in accordance with previous reports 
[24,25]. Mishina et al. [24] and Uchino et al. [25] reported that 
introduction of a point mutation, K445E, in the first QBP 
domain in GluRl led to a marked decrease in the apparant 
affinity for L-Glu, AMPA and quisqualate, suggesting that this 
amino acid is directly involved in agonist binding. Other muta- 
tions in the first QBP domain, namely E398K and D443K, also 
decreased the apparent agonist affinity [25]. Furthermore, 
recent experiments on the NMDA receptor subunit NMDA-Rl 
[40], indicate that amino acids located both in the first and 
second QBP domain are involved in binding of the co-agonist 
Gly to this receptor [41]. 
Further data supporting our results were very recently pre- 
sented by Stern-Bach et al. [42], who generated a number of 
chimeras from GluR3 and GluR6. Functionality was studied 
in Xenopus oocytes, and the pharmacological agonist profiles 
for the native and mutant receptors were determined. They 
concluded that the N-terminal region (first 400 amino acids) is 
not involved in agonist binding, but that two regions containing 
the first and the second QBP domain are involved and that 
simultaneous exchange of both regions is needed to fully re- 
verse the pharmacological profiles of GluR3 and GluR6. 
[‘HIAMPA and [3H]kainate binding were also performed (to 
transfected HeLa cells). However, the results from their radioli- 
gand binding studies are far from conclusive, as specific 
[3H]AMPA binding to the native GluR3 receptor could not be 
demonstrated. Furthermore, the determined affinities of 
[3H]AMPA and [3H]kainate for the mutant receptors (and for 
the native GluR6 receptor) are quite low, namely 100-300 nM. 
With affinities in that range a certain unreliability is introduced. 
Altogether, we have demonstrated that a domain, located 
between amino acid 1 and 400 in GluR2 and GluR6, showing 
homology to the leucineeisoleucineevaline transporter protein, 
LIVBP, is important for binding of the antagonists CNQX, 
DNQX, and NBQX. The LIVBP domain seems not to be im- 
portant for agonist binding. Another domain in GluR2 and 
GluR6, located between amino acids 400 and 500, which shows 
homology to a bacterial glutamine transporter protein, QBP, 
is directly involved in the binding of the agonists AMPA, ka- 
inate, and L-Glu. Also, a region located C-terminal to the first 
QBP domain is involved in binding of these three agonist, as 
well as in the binding of two other agonists, quisqualate and 
domoate. It is tempting to speculate that this C-terminal do- 
main is the second QBP domain. 
Acknowledgements: Our sincere thanks to Dr. Craig Blackstone (De- 
partment of Neuroscience, Howard Hughes Medical Institute, The 
John Hopkins University School of Medicine, Baltimore) for providing 
us with antibodies. Also sincere thanks to Dr. Jesper Rasmussen (De- 
partment of Molecular Biology II, Novo Nordisk A/S) for advice and 
help with the molecular biology. The work has been supported by 
grants to C.K.T. from the Danish Academy of Technical Sciences. 
References 
PI 
;z; 
141 
PI 
Bliss, T.V.P. and Collingridge, G.L. (1993) Nature 361, 31l 
39. 
Olney, J.W. (1990) Annu. Rev. Pharmacol. Toxicol. 30, 47-71. 
Monaghan, D.T., Bridges, R.J. and Cotman, C.W. (1989) Annu. 
Rev. Pharmacol. Toxicol. 29, 365402. 
Hollmann, M., O’Shea-Greenfield, A., Rogers, S.W. and Heine- 
mann, S. (1989) Nature 342, 643-648. 
Keinanen, K., Wisden, W. Sommer, B, Werner, P., Herb, A., 
Verdoorn, T.A., Sakmann, B. and Seeburg, P.H. (1990) Science 
249, 556-560. 
188 C.K. Tygesen et al. IFEBS Letters 363 (1995) 184-188 
[6] Boulter, J., Hollmann, M., O’Shea-Greenfield, A., Hartlet, M., 
Deneris, E., Maron, C. and Heinemann, S. (1990) Science 249, 
1033-1037. 
[7] Bettler, B., Boulter, J., Hermanns-Borgmeyer, I., O’Shea-Green- 
field, A., Deneris, E.S., Moll, C., Borgmeyer, U., Hollmann, M. 
and Heinemann, S. (1990) Neuron 5, 5833595. 
[8] Egebjerg, J., Bettler, B., Hermans-Borgmeyer, I. and Heinemann, 
S. (1991) Nature 351, 7455748. 
[9] Bettler, B., Egebjerg, J., Sharma, G., Pecht, G., Hermans- 
Borgmeyer, I., Moll, C., Stevens, CF. and Heinemann, S. (1992) 
Neuron 8, 257-265. 
1101 Werner, P., Voigt, M., Keinanen, K., Wisden, W. and Seeburg, P. 
(1991) Nature 351, 7422744. 
1111 Herb. A.. Burnashev. Werner. P.. Sakmann. B.. Wisden. W. and 
L > 
Seeburg, P. (1992) Neuron 8, 775-785. 
[12] Sommer, B., Kohler, M., Sprengel, R. and Seeburg, P.H. (1991) 
Cell 67, 1 l-19. 
[13] Hume, R.I., Dingledine, R. and Heinemann, S.F. (1991) Science 
253, 102881031. 
[14] Seeburg, P.H. (1993) Trends Neurosci. 16, 359-365. 
[15] Wo, Z.G. and Oswald, R.E. (1994) Proc. Natl. Acad. Sci. USA 91, 
7154- 7158. 
[16] Hollmann, M., Maron, C. and Heinemann, S. (1994) Neuron 13, 
1331-1343. 
[17] Monyer, H., Seeburg, P.H. and Wisden, W. (1991) Neuron 6, 
799-810. 
[18] Taverna, F.A., Wang, L.-Y., MacDonald, J.F. and Hampson, 
D.R. (1994) J. Biol. Chem. 19, 14159914164. 
[19] Roche, K.W., Raymond, L.A., Blackstone, C. and Huganir, R.L. 
(1994) J. Biol. Chem. 269, 11679-11682. 
[20] Nohno, T., Saito, T. and Hong, J.-S. (1986) Mol. Gen. Genet. 205, 
260-269. 
[21] Sack, J.S., Saper, M.A. and Quiocho, F.A. (1989) J. Mol. Biol. 
206, 171-191. 
[22] Nakanishi, N., Shneider, N.A. and Axe], R. (1988). Neuron 5, 
5699581. 
1231 O’Hara, P., Sheppard, P.O., Thogersen, H., Venezia, D., Halde- 
man, B.A., Mcdrane, V., Houamed, K.H., Thomsen, C., Gilbert, 
T.L. and Mulvihill. E.R. (1993). Neuron 11. 41-52. 
[24] Mishina, M., Sakimura, K., M&i, H., Kushiya, E., Harabayashi, 
M., Uchino, S. and Nagahari, K. (1991) Biochem. Biophys. Res. 
Commun. 180, 813-821. 
[25] Uchino, S., Sakimura, K., Nagahari, K. and Mishina, M. (1992) 
FEBS Lett. 308, 2533257. 
[26] Wada, K., Dechesne, C.J., Shimasaki, S., King, R.G., Kusano, K., 
Bounanno, A., Hampson, D.R., Banner, C., Wenthold, R.J. and 
Nakatani, Y. (1989) Nature 342, 684689. 
[27] Gregor, P., Eshhar, N., Ortega, A. and Teichberg, V.I. (1988) 
EMBO J. 7, 2673-2679. 
[28] Tygesen, C.K, Rasmussen, J.S, Nielsen, L.S, Egebjerg, J., An- 
dersen, P.H. (1994) 8th Sandbjerg Symposium, Sandbjerg, May 
25-27, 1994. 
[29] Tygesen, C.K., Rasmussen, J.S., Thastrup, O., Jorgensen, M. and 
Andersen, P.H. (1994). Sot. Neurosci. Abstr. 20, 1535. 
[30] Tygesen, C.K., Rasmussen, J.S., Jones, S.V.P., Hansen, A., 
Hansen, K. and Andersen, P.H. (1994) Proc. Natl. Acad. Sci. USA 
91, 13018-13022. 
[31] Sanger, F., Nicklen, S. and Coulson, A.R. (1977) Proc. Natl. Acad. 
Sci. USA 74, 546335467. 
[32] Petersen, L.C., Boel, E., Johannessen, M. and Foster, D. (1990) 
Biochemistry 29, 3451-3457. 
[33] Raymond, L.A., Blackstone, CD. and Huganir, R.L. (1993) Na- 
ture 361, 637-641. 
[34] Blackstone, CD., Levey, A.I., Martin, L.J., Price, D.L. and 
Huganir, R.L. (1992) Annu. Rev. Neurol. 31, 680-683. 
[35] Mayer, M.L. and Vyklicky, L. (1989) Proc. Natl. Acad. Sci. USA 
86, 141 l-1415. 
[36] Rasmussen, J.S., Nielsen, L.S., Hansen, A., Hansen, K., Boel, E., 
Houamed, K.H. and Andersen, P.H. (1992) Sot. Neurosci. Abstr. 
18, 260. 
[37] Houamed, K.H., Rasmussen, J.S., Nielsen, L.S., Hansen, A., 
Hansen, K., Boel, E. and Andersen, P.H. (1992) Sot. Neurosci. 
Abstr. 18, 260. 
[38] Lomeli, H., Wisden, W., Kohler, M., Keinanen, K., Sommer, B. 
and Seeburg, P.H. (1992) FEBS Latt. 2, 1399143. 
[39] Keinanen, K., Kohr, G., Seeburg, P.H., Laukkanen, M.-L. and 
Oker-Blom, C. (1994) BiolTechnology 12, 8022806. 
[40] Moriyoshi, K., Masu, M., Ishii, T., Shigemoto, R., Mizuno, N. 
and Nakanishi, S. (1991) Nature 354, 31-37. 
[41] Kuryatov, A., Laube, B., Betz, H. and Kuhse, J. (1994) Neuron 
12, 1291l1300. 
[42] Stern-Bach, Y., Bettler, B., Hartley, M., Sheppard, P.O., O’Hara, 
P.J. and Heinemann, S.F. (1994) Neuron 13, 134551357. 
